Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol-Enhanced MRI for CNS Inflammation
NCT02452216Phase 1Completed
- Start
- Jun 2015
- Primary completion
- Jan 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ferumoxytol in brain neoplasm, traumatic brain injury (TBI), neurodegenerative disease and 3 more. Primary endpoint: Measurements of iron concentration on T2*-weighted MR images at Day 1. Started Jun 2015; status: completed.
02
Drugs
ferumoxytol
03
Conditions
brain neoplasmtraumatic brain injury (TBI)neurodegenerative diseaseCentral nervous system infectionCentral nervous system vascular malformation (CNSVM)
Beyond the preview
Go deeper on NCT02452216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452216.